KR20160014568A - 전립선암을 치료하는 방법 - Google Patents

전립선암을 치료하는 방법 Download PDF

Info

Publication number
KR20160014568A
KR20160014568A KR1020157014380A KR20157014380A KR20160014568A KR 20160014568 A KR20160014568 A KR 20160014568A KR 1020157014380 A KR1020157014380 A KR 1020157014380A KR 20157014380 A KR20157014380 A KR 20157014380A KR 20160014568 A KR20160014568 A KR 20160014568A
Authority
KR
South Korea
Prior art keywords
androgen
prostate cancer
cdk8
cells
cdk19
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157014380A
Other languages
English (en)
Korean (ko)
Inventor
이고르 로닌슨
맹천 첸
Original Assignee
유니버시티 오브 싸우스 캐롤라이나
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 싸우스 캐롤라이나 filed Critical 유니버시티 오브 싸우스 캐롤라이나
Publication of KR20160014568A publication Critical patent/KR20160014568A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157014380A 2012-11-01 2013-11-01 전립선암을 치료하는 방법 Ceased KR20160014568A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721134P 2012-11-01 2012-11-01
US61/721,134 2012-11-01
PCT/US2013/067990 WO2014071143A1 (en) 2012-11-01 2013-11-01 Method for treating prostate cancer

Publications (1)

Publication Number Publication Date
KR20160014568A true KR20160014568A (ko) 2016-02-11

Family

ID=49641849

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157014380A Ceased KR20160014568A (ko) 2012-11-01 2013-11-01 전립선암을 치료하는 방법

Country Status (6)

Country Link
US (1) US9636342B2 (enExample)
EP (1) EP2914266B1 (enExample)
JP (1) JP6310470B2 (enExample)
KR (1) KR20160014568A (enExample)
CA (1) CA2890108C (enExample)
WO (1) WO2014071143A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106282378A (zh) * 2016-09-28 2017-01-04 湖北工业大学 一种用于细胞周期依赖性蛋白激酶8基因突变检测的试剂及应用
WO2019055977A1 (en) 2017-09-18 2019-03-21 Chan Zuckerberg Biohub, Inc. METHODS OF TREATING NEGATIVE TRIPLE BREAST CANCER
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CA3128377A1 (en) * 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005327921A1 (en) * 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
EP2547661A2 (en) * 2010-03-16 2013-01-23 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
EA027531B1 (ru) 2011-09-13 2017-08-31 Игорь Ронинсон ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB
KR20150023223A (ko) 2012-02-02 2015-03-05 세넥스 바이오테크놀러지 인코포레이티드 Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도

Also Published As

Publication number Publication date
CA2890108C (en) 2021-03-02
EP2914266A1 (en) 2015-09-09
JP2016501845A (ja) 2016-01-21
EP2914266B1 (en) 2019-06-19
US20150272953A1 (en) 2015-10-01
JP6310470B2 (ja) 2018-04-11
WO2014071143A1 (en) 2014-05-08
US9636342B2 (en) 2017-05-02
CA2890108A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
Burger et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function
Giró-Perafita et al. Preclinical evaluation of fatty acid synthase and EGFR inhibition in triple-negative breast cancer
Tsioumpekou et al. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression
Burbridge et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab
Bae et al. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
Yu et al. Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis
Baryawno et al. Tumor-growth–promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets
JP2022084888A (ja) 子宮頸がんを処置するためのグルココルチコイドレセプターモジュレーター
Li et al. Targeting the Hedgehog signaling pathway for cancer therapy
Galimberti et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe
EP3177308B1 (en) Use of peptides that block metadherin-snd1 interaction as treatment for cancer
EP3213752B1 (en) Composition for treating cancer stem cells
Dong et al. Myoferlin, a membrane protein with emerging oncogenic roles
KR20160014568A (ko) 전립선암을 치료하는 방법
K. Kandala et al. DIMming ovarian cancer growth
Xu et al. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+ PTEN− glioblastoma in vivo
Wozniak et al. Vemurafenib inhibits active PTK6 in PTEN-null prostate tumor cells
Lai et al. PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels
Lai et al. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors
TW201722422A (zh) 用於治療癌症之合理組合療法
Lin et al. The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells
EP3200801A1 (en) Methods of treating pancreatic cancer
Ge et al. Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma
Wu et al. Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo
EP2979708A1 (en) Composition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150529

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181101

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200121

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200629

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200121

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I